A treatment that could potentially slow the progression of amyotrophic lateral sclerosis (ALS) is being studied at the Montreal Neurological Institute-Hospital. Dr. Olivier Blanchard and his team want ...
Porter, an Army Physician, had just finished 15 years of service and went into private practice when she was diagnosed with ALS, more commonly known as Lou Gehrig's disease. “Feb 18, 2021 ...
Our sunflower season is short but sweet and while there might not be an abundance of sunflower farms in Aotearoa New Zealand, there are eight magical spots—including one in Tāmaki Makaurau ...
The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. Under the terms of the deal, Alchemab and Lilly will work together on up to five new ...
The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, and commercialize up to five novel therapeutics for the treatment of ...
Copyright 2025 The Associated Press. All Rights Reserved. A veteran Israeli journalist who has the degenerative disease ALS is to return to onscreen reporting thanks ...
Denali Therapeutics has announced topline results from the phase 2/3 Healey ALS Platform Trial, which evaluated the effects of its drug candidate DNL343. The study did not meet the primary efficacy ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...
A landmark study hoping to find new treatments for ALS has notched two more failures, as experimental medicines from Denali Therapeutics and Calico Life Sciences proved no better than a placebo at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback